NanoViricides Inc. (NNVC)

[changes_iv]

You mean like Rawnoc's touted marvel drug Fludase!?! Preclinical done quickly, in one fell swoop!

NexBio...

-A small-biotech that is privately-held
-with Fludase(TM) a first-in-class Influenza drug
-government begins to grease skids for the small-biotech, Aug 8, 2005?
-a 50m contract with the NIH, fast-tracked

Why would a privately-held company, that seemingly has everything going for them, would feel the urge to defraud the United States of America/taxpayers funded NIH? Cash-flow problems? with a 50m biologic-contract, how can that be?

Since its founding in 2003, NexBio has received at least $73 million in grants and contracts from the National Institutes of Health to develop and test Fludase, according to agency records and a 2009 report from the San Diego industry group Biocom.

After operating solely with government funding, the company in recent years tried to raise money from investors. It isn't clear whether those efforts were successful.

Company officials did not respond to several telephone and email messages.

source: http://www.sandiegouniontribune.com/news/2011/aug/04/feds-raid-san-diego-vaccine-developer/

Soon enough you will be reading about the third and final phase of the safety/toxicology studies, something like the following:

NanoViricides Reports FluCide™ Samples Were Shipped To BASi For Start of Safety/Toxicology Studies

WEST HAVEN, CONNECTICUT -- Wednesday, October 1, 2014 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that it has shipped FluCide™ to BASi for the start of toxicology studies. NanoViricides has chosen BioAnalytical Systems Inc. Toxicology Services ("BASi") of West Lafayette, Indiana to perform our safety/toxicology studies as needed for an IND submission of the Injectable FluCide drug candidate.

http://www.nanoviricides.com/press%20releases/2014/NanoViricides%20Reports%20FluCide%20Samples%20Were%20Shipped%20To%20BASi%20For%20Start%20of%20Safety%20Toxicology%20Studies%20Also%20Reports%20That%20Ebola%20Drug%20Candidates%20are%20Being%20Synthesized.html

We are currently making the FluCide(TM) material...

...In addition, we continue to perform step-wise scale up of production to enable multi-kg batches of our injectable anti-Influenza drug candidate for IND-enabling “Tox Package” studies. These studies are estimated to require up to 2.5 kg of the drug substance. We plan on scaling up from the 200g scale to 500g scale and then to 1kg scale. We may be able to combine several batches at either the 500g scale or at the 1 kg scale, provided that they are sufficiently equivalent in the characterization studies, in order to prepare a single master batch for further Tox Package studies. In the meantime, we have already performed preliminary safety/toxicology studies in rats using 200g material produced in our older R&D facilities in West Haven, CT. These studies have demonstrated excellent safety of FluCide. Previously, we have performed preliminary safety studies in mice as well. Those studies demonstrated excellent safety of FluCide. This led to the calculation of a very large quantity for our ensuing “Tox Package” studies for this drug candidate.

June 1, 2015, 9:47 PM
FluCide

Phase I and II of tox successfully completed

Making material for last Phase in large animals
.
.
.
Had FluCide not turned out to be so incredibly safe, we would have been done with tox by now. Incredibly safe is not a bad thing at all!

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

=============================================

"I suppose" the "con blogger", "Pump Terminator", could soon be coming out of his closet to reiterate everything he has blogged in the past about our small company, plus an update on why he/she/they believe the risk has jumped from 80% to 99%. "I must confess", I feel pretty confident the sociopath/white-collar criminal will not be outdoing himself and instead rely solely on minimum wage cons/alias/anonymous posters.

Recent “Bear” Attack

As many of you know, a malicious and possibly criminal attack on our common stock was carried out on February 11, 2014, through the publication of a false and misleading article on Seeking Alpha. The intent of the article was to dramatically drive down our stock price. The article resulted in a highly increased daily trading volume of eight million shares, approximately 20 times our daily average. The information we have gathered suggests that this was an organized attack using false and inaccurate information designed to benefit short sellers in the stock. We have reported this conduct to the regulatory authorities and have retained legal counsel to investigate both the website that hosted this article and the anonymous blogger who authored it.

www.nanoviricides.com/2014-ceo-letter.pdf